DPCA2-1

More documents

Recommendations

Info

What primary care clinicians should know about fenofibrate for people with diabetes Table 2. Percentage reduction of vascular complications with fenofibrate relative to placebo in the FIELD and ACCORD Lipid studies. Outcomes FIELD ACCORD Lipid Primary outcomes* -11 (Keech et al, 2005) Secondary outcomes Silent myocardial infarction -16 (Burgess et al, 2010) Not available Death from cardiovascular cause † -4 (Burgess et al, 2010) Coronary revascularisation ‡ -21 (Keech et al, 2005) Stroke (fatal or non-fatal) -10 (Keech et al, 2005) Any amputation due to diabetes Microvascular outcomes -36 (Rajamani et al, 2009) Not available Retinopathy § -37 (Keech et al, 2007) Albuminuria || -14 (Keech et al, 2005; Davis et al, 2011) First minor (only) amputation -46 (Rajamani et al, 2009) Not available -8 (ACCORD Study Group, 2010a) -14 (ACCORD Study Group, 2010a) -6 (ACCORD Study Group, 2010a) +5 (ACCORD Study Group, 2010a) -40 (ACCORD Study Group, 2010b) -8 (ACCORD Study Group, 2010a) *FIELD: First myocardial infarction or coronary heart disease death; ACCORD Lipid: First non-fatal myocardial infraction or stroke or death from cardiovascular causes. † FIELD: Fatal myocardial infarction; ACCORD Lipid: Death from cardiovascular cause. ‡ FIELD: Coronary revascularisation; ACCORD Lipid: Revascularisation or hospitalisation for congestive heart failure (together with primary outcome). § FIELD: All events, laser treatment; ACCORD Lipid: Laser treatment and/or vitrectomy and/or 3-step Early Treatment Diabetic Retinopathy (ETDR) scale progression. || FIELD: Progression (normo- to microalbuminuria or from micro- to macroalbuminuria) separately, FIELD study also reported a significant 18% increase in albuminuria regression (from macro- to microalbuminuria or from micro- to normoalbuminuria) in response to fenofibrate therapy versus placebo (Keech et al, 2005; Davis et al, 2011); ACCORD Lipid: microalbuminuria incidence (postrandomisation). P
What primary care clinicians should know about fenofibrate for people with diabetes with low rates (
Page 1 and 2: Diabetes & Primary Care Australia V
Page 3 and 4: Contents Diabetes & Primary Care Au
Page 5 and 6: Editorial Diabetes education We are
Page 7 and 8: From the desktop From the desktop P
Page 9 and 10: From the desktop dose, I have also
Page 11 and 12: Diabetes education: Essential but u
Page 13 and 14: Diabetes education: Essential but u
Page 15 and 16: Save the date: The 2 nd PCDSA Natio
Page 17 and 18: Clinical vascular screening of the
Page 25 and 26: Article Antimicrobial management of
Page 27 and 28: Antimicrobial management of diabeti
Page 29 and 30: Antimicrobial management of diabeti
Page 31: What primary care clinicians should
Page 35 and 36: Article Glucagon-like peptide-1 ana
Page 37 and 38: Glucagon-like peptide-1 analogues -
Page 39 and 40: Glucagon-like peptide-1 analogues -

DPCA2-1

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?